Assessment and Improvement of Liver Specific Function of the AMC-Bioartificial Liver

The variety of methods for measuring bioactive mass and functionality of bioartificial livers (BAL) is confusing and prevents accurate comparison of reported data. Here we present a comparison of different hepatocyte quantification methods and propose that estimation of cell pellet volume after centrifugation generates a reliable, useful and fast method. In addition a correlation is made between several function tests performed in 26 bioreactors to assess their predictive value. The ammonia eliminating capacity was found to be most predictive for other liver functions, except for lidocaine elimination as a measure of mixed function oxidase activity, which should therefore be determined separately. The oxygen consumption test proved to be an easy and predictive parameter as well. The first generation of our BAL system needed further development to assure optimal treatment of acute liver failure (ALF) patients. Changes in the porcine hepatocyte isolation method and bioreactor loading as well as changes in bioreactor configuration, including use of different materials, resulted in a significantly improved level and maintenance of in vitro BAL function. A fourfold increase in ammonia eliminating capacity, which is only reduced to 75% after seven days of culturing, offers promising prospects for further clinical application. Conclusion The current second generation of our BAL and improvement of hepatocyte isolation and testing protocols have led to a significant increase in the level as well as the maintenance of hepatocyte specific function in our BAL. Finally, consensus on definition of the bioactive mass to be loaded in the bioreactor and insight in the variation and reliability of the functional and metabolic parameters enhances comparison of the different types of bioartificial livers presented in literature.

[1]  T. K. Baker,et al.  Temporal gene expression analysis of monolayer cultured rat hepatocytes. , 2001, Chemical research in toxicology.

[2]  M. Berry,et al.  Isolated Hepatocytes: Preparation, Properties and Applications , 1991 .

[3]  L. Flendrig,et al.  Significantly Improved Survival Time in Pigs with Complete Liver Ischemia Treated with a Novel Bioartificial Liver , 1999, The International journal of artificial organs.

[4]  L. Flendrig,et al.  Commercially Available Media for Flushing Extracorporeal Bioartificial Liver Systems Prior to Connection to the Patient's Circulation: An in vitro Comparative Study in Two and Three Dimensional Porcine Hepatocyte Cultures , 1998, The International journal of artificial organs.

[5]  Thomas M van Gulik,et al.  ASSESSMENT OF THE AMC-BIOARTIFICIAL LIVER IN THE ANHEPATIC PIG1 , 2002, Transplantation.

[6]  R. Chamuleau,et al.  Bridging a Patient with Acute Liver Failure to Liver Transplantation by the AMC-Bioartificial Liver , 2003, Cell transplantation.

[7]  L. Flendrig,et al.  Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver. , 1995, Journal of hepatology.

[8]  Thomas M van Gulik,et al.  Clinical Application of Bioartificial Liver Support Systems , 2004, Annals of surgery.

[9]  Y. Yamaoka,et al.  Long-term culture of primary human hepatocytes with preservation of proliferative capacity and differentiated functions. , 2002, The Journal of surgical research.

[10]  M. Sosef,et al.  Treatment of Acute Liver Failure in Pigs Reduces Hepatocyte Function in a Bioartificial Liver Support System , 2002, The International journal of artificial organs.

[11]  R. Chamuleau,et al.  Blood coagulation in anhepatic pigs: effects of treatment with the AMC‐bioartificial liver , 2003, Journal of thrombosis and haemostasis : JTH.

[12]  A. Bader,et al.  A Novel Full‐Scale Flat Membrane Bioreactor Utilizing Porcine Hepatocytes: Cell Viability and Tissue‐Specific Functions , 2000, Biotechnology progress.

[13]  L. Flendrig,et al.  Semipermeable hollow fiber membranes in hepatocyte bioreactors: a prerequisite for a successful bioartificial liver? , 2008, Artificial organs.

[14]  M. McCarter,et al.  Metastatic liver tumors. , 2000, Seminars in surgical oncology.

[15]  Does the Extend of the Culture Time of Primary Hepatocytes in a Bioreactor Affect the Treatment Efficacy of a Bioartificial Liver? , 1998, The International journal of artificial organs.

[16]  L. Flendrig,et al.  Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. , 1999, Journal of hepatology.

[17]  O. Greengard,et al.  CYTOMORPHOMETRY OF DEVELOPING RAT LIVER AND ITS APPLICATION TO ENZYMIC DIFFERENTIATION , 1972, The Journal of cell biology.

[18]  R. DeMatteo,et al.  Surgical treatment of malignant liver tumours. , 1999, Bailliere's best practice & research. Clinical gastroenterology.

[19]  R. Hoekstra,et al.  Phase I Clinical Trial with the AMC-Bioartificial Liver , 2002 .

[20]  Hans Rudolf Gnägi,et al.  CORRELATED MORPHOMETRIC AND BIOCHEMICAL STUDIES ON THE LIVER CELL , 1969, The Journal of cell biology.

[21]  A. Puviani,et al.  Biologic Liver Support: Optimal Cell Source and Mass , 2002, The International journal of artificial organs.

[22]  O. Karlsen,et al.  UvA-DARE ( Digital Academic Repository ) In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates , 2001 .